SCHEMBL3436690

SCHEMBL3436690

Cc1cc(Cl)ccc1-c1nc(C)c(CO)s1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
PTGDR2 Q9Y5Y4 1/20 0.42
MAPT P10636 5/20 0.41
LMNA P02545 2/20 0.40
THRB P10828 2/20 0.40
NOTUM Q6P988 1/20 0.37
CRHR1 P34998 1/20 0.36
TRPV1 Q8NER1 1/20 0.36
CASP3 P42574 2/20 0.36
SHMT1 P34896 1/20 0.36
SHMT2 P34897 1/20 0.36
RAB9A P51151 2/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3436694 0.85 KDM4E (0.43) KDM4EKMT2AMEN1ALDH1A1PTGDR2
SCHEMBL3435491 0.83 HSP90AA1 (0.44) KDM4EALDH1A1PTGDR2MAPTLMNA
SCHEMBL3436697 0.82 MAPT (0.41) MAPTLMNATHRBTP53
SCHEMBL3436689 0.78 TRPM8 (0.41) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL95917 0.78 RAB9A (0.56) KDM4EKMT2AMEN1ALDH1A1PTGDR2
SCHEMBL3436684 0.77 CDC7 (0.44) KDM4EMAPTLMNATHRBRAB9A
SCHEMBL14960175 0.77 CASP3 (0.41) KDM4EKMT2AALDH1A1MAPTNOTUM
SCHEMBL19936600 0.76 CASP3 (0.40) KDM4EKMT2AALDH1A1MAPTNOTUM
SCHEMBL3371195 0.76 ALDH1A1 (0.50) KDM4EKMT2AMEN1ALDH1A1MAPT
SCHEMBL3436648 0.75 KDM4E (0.65) KDM4EKMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI KDM4E 1069/4885KMT2A 1012/4885MEN1 1700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.